Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

ClinicalTrials.gov ID: NCT02514577

Public ClinicalTrials.gov record NCT02514577. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).

Study identification

NCT ID
NCT02514577
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bausch Health Americas, Inc.
Industry
Enrollment
217 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 6, 2015
Primary completion
Apr 30, 2017
Completion
Apr 30, 2017
Last update posted
Jan 26, 2020

2015 – 2017

United States locations

U.S. sites
15
U.S. states
11
U.S. cities
15
Facility City State ZIP Site status
Valeant Site 11 Hot Springs Arkansas 71901
Valeant Site 1 Encinitas California 92023
Valeant Site 10 Encino California 91436
Valeant Site 12 Santa Rosa California 95401
Valeant Site 13 Atlanta Georgia 30301
Valeant Site 7 Boise Idaho 83701
Valeant Site 6 Rockville Maryland 20847
Valeant Site 4 Ann Arbor Michigan 48103
Valeant Site 8 Clarkston Michigan 48346
Valeant Site 15 Las Vegas Nevada 89101
Valeant Site 9 Raleigh North Carolina 27601
Valeant Site 5 Knoxville Tennessee 37901
Valeant Site 3 Austin Texas 73301
Valeant Site 2 San Antonio Texas 78201
Valeant Site 14 Spokane Washington 99201

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02514577, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 26, 2020 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02514577 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →